Search the Newsreel

Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Tyra Biosciences Inc (TYRA), detailing various metrics related to volatility, financial risk, and investment risk. It includes data points such as Beta, Value at Risk (VaR), maximum drawdown, daily returns, Sharpe Ratio, and liquidity. The report offers …

Tyra Biosciences Inc|Price:30.630|Chg%:-0.170

This article provides an overview of Tyra Biosciences Inc. (TYRA) stock, showing its current price, change, and market capitalization. It highlights that no stock score is available due to insufficient data but details how TradingKey generates its comprehensive stock scores, covering financial health, valuation, …

Tyra Biosciences (TYRA) Proxy filing Summary

Tyra Biosciences is holding its Annual Meeting on May 28, 2026, virtually. Shareholders will vote on the election of three Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December …

Tyra Biosciences (TYRA) Q4 2025 earnings summary

Tyra Biosciences (TYRA) reported its Q4 2025 earnings, highlighting a strategic focus on three late-stage clinical studies for its dabogratinib program and an enhanced leadership team. Financially, the company ended 2025 with $256.0 million in cash, providing a runway through at least 2027, despite …

Tyra Biosciences (TYRA) Bank of America Global Healthcare Conference 2026 Summary

Tyra Biosciences presented at the Bank of America Global Healthcare Conference 2026, highlighting the advancement of its highly selective FGFR3 inhibitor, dabogratinib, into late-stage development for three potential blockbuster indications: intermediate-risk NMIBC, UTUC, and achondroplasia. The company anticipates pivotal data readouts, including a 70% …

Jennison Associates LLC Buys Shares of 632,432 Tyra Biosciences, Inc. $TYRA